516 patents
Page 5 of 26
Utility
Ruxolitinib formulation for reduction of itch in atopic dermatitis
28 Feb 23
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, Jim Lee
Filed: 28 Mar 22
Utility
Topical treatment of vitiligo by a jak inhibitor
28 Feb 23
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Kathleen Butler, Jim Lee, Kang Sun, Fiona Kuo, Michael Howell
Filed: 8 Jul 22
Utility
Bipyrazole derivatives as JAK inhibitors
28 Feb 23
Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
Filed: 13 Apr 21
Utility
Bicyclic heterocycles as FGFR inhibitors
28 Feb 23
Oleg Vechorkin, Chao Qi, Minh Nguyen, Anlai Wang, Wenqing Yao
Filed: 8 Jul 20
Utility
Pyrrolotriazine compounds as TAM inhibitors
28 Feb 23
Yun-Long Li, Xiaozhao Wang, Chunhong He
Filed: 19 Oct 20
Utility
Tricyclic Compounds As Inhibitors of Kras
23 Feb 23
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds.
Pei Gan, Jeffrey Yang, Yong Li, Le Zhao, Chunhong He, Chunyin Marshall Law, Xiaozhao Wang, Wenqing Yao
Filed: 6 Jul 22
Utility
Process and Intermediates for Preparing a Jak Inhibitor
23 Feb 23
The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.
Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Pingli Liu, David Meloni, Yongchun Pan, Naijing Su, Michael Xia
Filed: 11 Jul 22
Utility
Biomarkers for inflammatory skin disease
21 Feb 23
Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor.
Michael D. Howell, Huiqing Liu
Filed: 29 Mar 19
Utility
Sustained-release dosage forms of ruxolitinib
14 Feb 23
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Filed: 23 Jun 22
Utility
Sustained-release dosage forms of ruxolitinib
14 Feb 23
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Filed: 23 Jun 22
Utility
PIPERIDIN-4-YL Azetidine Derivatives As JAK1 Inhibitors
9 Feb 23
The present invention provides piperidin-4-y1 azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Taisheng Huang, Chu-Biao Xue, Hui-Yin Li, Qun Li, Anlai Wang, Lingquan Kong, Hai Fen Ye, Wenqing Yao, James D. Rodgers, Stacey Shepard, Haisheng Wang, Lixin Shao
Filed: 17 Feb 22
Utility
Topical formulation for a JAK inhibitor
7 Feb 23
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 25 Mar 22
Utility
Heterocyclic compounds as immunomodulators
7 Feb 23
Jingwei Li, Liangxing Wu, Wenqing Yao
Filed: 24 Aug 20
Utility
Pyrazolopyridines and Triazolopyridines As A2A / A2B Inhibitors
2 Feb 23
Taisheng Huang, Xiaozhao Wang
Filed: 15 Jun 22
Utility
Heterocyclic compounds as immunomodulators
31 Jan 23
Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
Filed: 15 Sep 20
Utility
Bicyclic heterocycles as FGFR inhibitors
31 Jan 23
Artem Shvartsbart, Jeremy Roach, Wenqing Yao
Filed: 15 Oct 20
Utility
Biomarkers for Graft-versus-host Disease
26 Jan 23
Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor.
Michael D. Howell, Hao Liu, Michael A. Pratta
Filed: 20 May 22
Utility
Imidazolyl Pyrimidinylamine Compounds As CDK2 Inhibitors
26 Jan 23
The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Qinda Ye, Jingwei Li, Ken Mukai, Brandon Smith, Liangxing Wu, Wenqing Yao, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
Filed: 29 Jul 22
Utility
HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
12 Jan 23
Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
Filed: 24 Jun 21
Utility
Bicyclic Pyrazolyl Amines As CDK2 Inhibitors
5 Jan 23
Joshua Hummel, Jingwei Li, Ding-Quan Qian, Liangxing Wu
Filed: 21 Jun 22